Niklas Norén
Niklas Norén
Chief Science Officer, Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug
Geverifieerd e-mailadres voor who-umc.org
Geciteerd door
Geciteerd door
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
Temporal pattern discovery in longitudinal electronic patient records
GN Norén, J Hopstadius, A Bate, K Star, IR Edwards
Data Mining and Knowledge Discovery 20 (3), 361-387, 2010
Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events
GN Norén, A Bate, R Orre, IR Edwards
Statistics in medicine 25 (21), 3740-3757, 2006
Suspected adverse drug reactions reported for children worldwide
K Star, GN Norén, K Nordin, IR Edwards
Drug safety 34 (5), 415-428, 2011
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
GN Norén, J Hopstadius, A Bate
Statistical methods in medical research 22 (1), 57-69, 2013
A statistical methodology for drug–drug interaction surveillance
GN Norén, R Sundberg, A Bate, IR Edwards
Statistics in medicine 27 (16), 3057-3070, 2008
vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues
T Bergvall, GN Norén, M Lindquist
Drug safety 37 (1), 65-77, 2014
Duplicate detection in adverse drug reaction surveillance
GN Norén, R Orre, A Bate, IR Edwards
Data Mining and Knowledge Discovery 14 (3), 305-328, 2007
Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase®
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug safety 40 (1), 81-90, 2017
Good signal detection practices: evidence from IMI PROTECT
AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ...
Drug safety 39 (6), 469-490, 2016
Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database
O Caster, GN Norén, D Madigan, A Bate
Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank
O Caster, K Juhlin, S Watson, GN Norén
Drug safety 37 (8), 617-628, 2014
Temporal pattern discovery for trends and transient effects: its application to patient records
GN Norén, A Bate, J Hopstadius, K Star, IR Edwards
Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008
Impact of stratification on adverse drug reaction surveillance
J Hopstadius, GN Norén, A Bate, IR Edwards
Drug safety 31 (11), 1035-1048, 2008
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest
RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ...
Drug safety 37 (8), 557-567, 2014
Earlier discovery of pregabalin’s dependence potential might have been possible
O Caster, IR Edwards, GN Norén, M Lindquist
European journal of clinical pharmacology 67 (3), 319-320, 2011
A hit-miss model for duplicate detection in the WHO drug safety database
GN Norén, R Orre, A Bate
Proceedings of the eleventh ACM SIGKDD international conference on Knowledge …, 2005
Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR
J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ...
Drug Safety 42 (12), 1393-1407, 2019
Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second‐generation antipsychotics
J de Leon, EJ Sanz, GN Norén, C De las Cuevas
World Psychiatry 19 (1), 120, 2020
Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance
GN Norén, O Caster, K Juhlin, M Lindquist
Drug safety 37 (9), 655-659, 2014
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20